Exploring neuroplasticity mechanisms in stroke rehabilitation: Implications for therapeutic approaches

Since you don't know how neuroplasticity works, how EXACTLY ARE YOUR MEASURING IT?

You haven't identified the EXACT signals between neurons that tell one neuron to drop their use and take on a neighboring neuron's use! That could then make neuroplasticity repeatable on demand.  Until that occurs ALL OF THIS SUPPOSED NEUROPLASTICITY RESEARCH IS ALMOST COMPLETELY FUCKING USELESS!

 Exploring neuroplasticity mechanisms in stroke rehabilitation: Implications for therapeutic approaches

Mikael Juhani Virtanen and Elina Katariina Korhonen DOI: https://www.doi.org/10.33545/26646161.2026.v8.i1a.57 

 Abstract 

 The brain's capacity to rewire itself after stroke is both the greatest source of hope in neurorehabilitation and, paradoxically, one of the least predictable factors governing individual recovery trajectories. This research examined neuroplasticity mechanisms and their relationship to functional outcomes across five rehabilitation approaches in 169 ischemic stroke patients treated at two Finnish university hospitals between May 2021 and February 2022. Patients were assigned to conventional physiotherapy (n=38), constraint-induced movement therapy (n=34), repetitive transcranial magnetic stimulation combined with physiotherapy (n=33), transcranial direct current stimulation with physiotherapy (n=32), or robot-assisted therapy (n=32) based on clinical assessment and patient preference. Brain-derived neurotrophic factor levels, functional MRI cortical activation patterns, and Fugl-Meyer Assessment scores were measured at baseline, weeks 4, 8, and 12, and at six months post-stroke. BDNF elevation was the most commonly observed neuroplasticity marker, present in 32.7% of patients as the primary mechanism, followed by cortical remapping (24.1%) and synaptogenesis markers (18.9%). Constraint-induced movement therapy and rTMS combined protocols produced the largest Fugl-Meyer gains at six months (56.8 and 54.6 respectively, compared with 46.2 for conventional therapy, both p<0.01). Serum BDNF levels increased most rapidly in rTMS recipients, reaching 33.7 ng/mL at week 12 versus 24.8 ng/mL in conventional therapy (p<0.001). Patients achieving excellent functional recovery (modified Rankin Scale 0-1) represented 28.4% of the cohort, while 13.1% showed poor outcomes despite rehabilitation. Baseline BDNF concentration above 20 ng/mL predicted favorable six-month outcomes with 74.3% sensitivity and 68.1% specificity. The neuroplasticity-guided rehabilitation protocol we developed stratifies patients into high, moderate, and low neuroplastic potential categories to guide intervention selection. These findings suggest that measuring neuroplasticity biomarkers early after stroke can inform personalized rehabilitation planning and that neuromodulatory interventions meaningfully enhance neuroplastic responses beyond what conventional approaches achieve alone. 

 Keywords: Neuroplasticity, stroke rehabilitation, brain-derived neurotrophic factor, transcranial magnetic stimulation, constraint-induced movement therapy, cortical remapping, Fugl-Meyer Assessment, biomarker prediction, neuromodulation